Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8NDZ2
UPID:
SIMC1_HUMAN
Alternative names:
Platform element for inhibition of autolytic degradation
Alternative UPACC:
Q8NDZ2; F6R0L0; J3KQQ8; Q6NXN8; Q6ZTU4; Q8IZ15; R9TJD7
Background:
SUMO-interacting motif-containing protein 1, alternatively known as Platform element for inhibition of autolytic degradation, plays a crucial role in viral restriction. It is instrumental in the recruitment of the SMC5-SMC6 complex to PML nuclear bodies and sites of viral replication through its complex formation with SLF2. Additionally, it inhibits the protease activity of CAPN3, showcasing its multifunctional biological significance.
Therapeutic significance:
Understanding the role of SUMO-interacting motif-containing protein 1 could open doors to potential therapeutic strategies.